Singapore: Jazz Pharmaceuticals reported earnings worth $208.3 million in revenue during the second quarter of 2013, an increase from $124.2 million in the same quarter of 2012.

The increase in total revenues for the quarter ending June 30, 2013, was driven primarily by increased net sales of Xyrem and the inclusion of Erwinaze product sales for the full reporting period in 2013.

"During the second quarter, we continued our track record of delivering strong top and bottom line growth fueled by increasing sales of Xyrem and Erwinaze," said Mr Bruce Cozadd, chairman and chief executive officer, Jazz Pharmaceuticals.

"We remain committed to creating long-term shareholder value through disciplined investments to support expansion in our research and development, commercial and operational capacities and pursuit of promising corporate development opportunities," he added.